<DOC>
	<DOCNO>NCT01204398</DOCNO>
	<brief_summary>The primary objective trial evaluate change baseline ( Visit 2 ) 24-hour Ambulatory Blood Pressure Monitoring mean ( relative dose time ) diastolic blood pressure systolic blood pressure 8 week treatment Telmisartan 80mg/Amlodipine 5mg patient moderate severe hypertension</brief_summary>
	<brief_title>Telmisartan+Amlodipine Fixed Dose Combination Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : 1 . Aged least 18 year date signing consent form 2 . For treatmentna√Øve patient : hypertension define mean seat diastolic blood pressure ( DBP ) equal 100 mmHg measure manual cuff sphygmomanometry visit 1 2 ; For pretreatment patient : hypertension define mean seat diastolic blood pressure equal 90 mmHg visit 1 equal 100 mmHg visit 2 measure manual cuff sphygmomanometry 3 . 24hour mean diastolic blood pressure equal 85 mmHg baseline Ambulatory Blood Pressure Monitoring Exclusion criterion : 1. mean seat systolic blood pressure equal 200 mmHg and/or mean seat diastolic blood pressure equal 120 mmHg 2. clinically significant hepatic impairment 3. severe renal impairment 4. bilateral renal artery stenosis renal artery stenosis solitary kidney postrenal transplant 5. current treatment antihypertensive agent , whether prescribed indication , safely stop 6. condition situation could put potential participant unacceptable risk due participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>